TABLE 1.
Antibody responsea elicited by rCBD via subcutaneous immunization
| Antiserum against rCBDb derived from | Antibody titer to nHaps-P860295 |
|---|---|
| GST-rCBDN187 FP | 58,050 |
| GST-rCBDP860295 FP | 97,739 |
| GST-rCBDTN106 FP | 14,833 |
| rCBDN187 IB | 32,440 |
| Preimmune sera | <100 |
| Control antiserum against E. coli lysatec | <100 |
a
Mice were immunized subcutaneously with rCBD mixed with MPL and aluminum phosphate. Preimmune era and week 6 sera pooled from 10 mice were analyzed for antibody titer to purified nHapS-P860295.
b
rCBD was generated from soluble GST-rCBD fusion protein (FP) or urea-solubilized inclusion bodies (IB).
c
Control antiserum against an induced BL21 (DE3)/pLysS/pGEX-6P-1 cell lysate.